Pathology, Lund
1 – 10 of 251
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
A bottom-up initiated digital external quality assessment scheme for the state-of-the-art pathology in Sweden : reduced variability between pathology departments
(2025) In Virchows Archiv
- Contribution to journal › Article
-
Mark
Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma
- Contribution to journal › Article
-
Mark
Precision Omics Initiative Sweden (PROMISE) will integrate research with healthcare
- Contribution to journal › Letter
-
Mark
High prevalence of atrial conduction abnormalities in Lewy body disease – a marker of cardiac complications?
- Contribution to journal › Article
-
Mark
The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue
- Contribution to journal › Article
-
Mark
PD-L1 in lung cytology: the path for standardization
(2025) In Acta Cytologica
- Contribution to journal › Scientific review
-
Mark
Localization, Proteolytic Processing, and Binding Partners of Versican Isoforms in Vascular Lesions of Pulmonary Arterial Hypertension
(2025) In The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 73(3-4). p.129-145
- Contribution to journal › Article
-
Mark
Global Transcriptional Complexity of Estrogen Receptor Low Positive Breast Cancers in a Prospective Swedish Population-based SCAN-B Cohort
(2025) In Clinical cancer research : an official journal of the American Association for Cancer Research 31(13). p.2695-2709
- Contribution to journal › Article
-
Mark
In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC
- Contribution to journal › Article
-
Mark
Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
- Contribution to journal › Article
